T cell receptor gamma locus antisense RNA 1 (TRG-AS1)

T cell receptor gamma locus antisense RNA 1 (TRG-AS1) is a human long noncoding RNA (lncRNA) transcribed antisense to the T cell receptor gamma locus. TRG-AS1 is not a protein-coding gene, but functions as a regulatory RNA, frequently acting as a competing endogenous RNA (ceRNA) that can sequester specific microRNAs and thereby modulate the expression of oncogenic transcription factors (for example BACH1 in hepatocellular carcinoma, YAP1 in tongue squamous cell carcinoma, and SUZ12 in glioblastoma)[1][3][10]. TRG-AS1 is implicated in tumor progression by promoting proliferation, migration, invasion, and epithelial-mesenchymal transition. It is overexpressed in several types of cancer, correlating with advanced disease and poor prognosis. Because of its functional role in cancer cell biology and the tractability of lncRNAs to nucleic acid-based therapeutics, TRG-AS1 is being explored as both a biomarker and a therapeutic target in oncology[1][3][6][7][10].

Other names

TRG antisense RNA 1TCRGVTRG-AS1T cell receptor gamma locus antisense RNA 1ENSG00000281103NCBI 100506776[4][5][7]

Acts as a molecular sponge for microRNAs (e.g., miR-4500 in HCC, miR-543 in TSCC, miR-877-5p in glioblastoma), thereby regulating target gene expression (e.g., BACH1, YAP1, SUZ12) and promoting oncogenicity[1][3][10] - Targeted by nucleic acid therapeutics to silence its function (experimental/therapeutic mechanism)[7]